PartnershipApr 29, 2026, 08:07 AM
CADL Partners with EVERSANA for CAN-2409 US Commercial Launch
AI Summary
Candel Therapeutics, Inc. (CADL) announced a product commercialization agreement with EVERSANA to support the potential U.S. launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk, localized prostate cancer. EVERSANA will provide a broad suite of integrated commercialization services, joining IDEA Pharma in pre-commercial workstreams. This collaboration establishes a partner-led commercial model designed to leverage world-class capabilities while maintaining Candel's financial flexibility and scientific focus, ahead of a planned BLA submission in Q4 2026.
Key Highlights
- Candel Therapeutics (CADL) partnered with EVERSANA for U.S. commercial launch of CAN-2409.
- EVERSANA will provide integrated commercialization services including data, medical affairs, and market access.
- CAN-2409 is for intermediate- to high-risk, localized prostate cancer.
- Candel plans a Biologics License Application (BLA) submission for CAN-2409 in Q4 2026.
- The partner-led model aims to provide commercial capabilities while maintaining financial flexibility.
- IDEA Pharma is also collaborating on path-to-market strategies for aglatimagene.
- CAN-2409 has FDA Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations.
Price Impact
More from CADL